

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Harfouche, Manale; Chemaitelly, Hiam; Kouyoumjian, Silva P; Mahmud, Sarwat; Chaabna, Karima; Al-Kanaani, Zaina; Abu-Raddad, Laith J; (2017) Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions. PLOS ONE, 12 (10). ISSN 1932-6203 DOI: <https://doi.org/10.1371/journal.pone.0187177>

Downloaded from: <http://researchonline.lshtm.ac.uk/4652329/>

DOI: <https://doi.org/10.1371/journal.pone.0187177>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by/2.5/>

<https://researchonline.lshtm.ac.uk>

RESEARCH ARTICLE

# Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions

Manale Harfouche<sup>1</sup>, Hiam Chemaitelly<sup>1</sup>, Silva P. Kouyoumjian<sup>1</sup>, Sarwat Mahmud<sup>1</sup>, Karima Chaabna<sup>1,2</sup>, Zaina Al-Kanaani<sup>1</sup>, Laith J. Abu-Raddad<sup>1,2\*</sup>

**1** Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar, **2** Department of Healthcare Policy & Research, Weill Cornell Medicine, Cornell University, New York, United States of America

\* [lja2002@qatar-med.cornell.edu](mailto:lja2002@qatar-med.cornell.edu)



## Abstract

### Objectives

To estimate hepatitis C virus (HCV) viremic rate, defined as the proportion of HCV chronically infected individuals out of all ever infected individuals, in the Middle East and North Africa (MENA).

### Methods

Sources of data were systematically-gathered and standardized databases of the MENA HCV Epidemiology Synthesis Project. Meta-analyses were conducted using DerSimonian-Laird random-effects models to determine pooled HCV viremic rate by risk population or subpopulation, country/subregion, sex, and study sampling method. Random-effects meta-regressions were conducted to identify predictors of higher viremic rate.

### Results

Analyses were conducted on 178 measures for HCV viremic rate among 19,593 HCV antibody positive individuals. In the MENA region, the overall pooled mean viremic rate was 67.6% (95% CI: 64.9–70.3%). Across risk populations, the pooled mean rate ranged between 57.4% (95% CI: 49.4–65.2%) in people who inject drugs, and 75.5% (95% CI: 61.0–87.6%) in populations with liver-related conditions. Across countries/subregions, the pooled mean rate ranged between 62.1% (95% CI: 50.0–72.7%) and 70.4% (95% CI: 65.5–75.1%). Similar pooled estimates were further observed by risk subpopulation, sex, and sampling method. None of the hypothesized population-level predictors of higher viremic rate were statistically significant.

### Conclusions

Two-thirds of HCV antibody positive individuals in MENA are chronically infected. Though there is extensive variation in study-specific measures of HCV viremic rate, pooled mean estimates are similar regardless of risk population or subpopulation, country/subregion,

## OPEN ACCESS

**Citation:** Harfouche M, Chemaitelly H, Kouyoumjian SP, Mahmud S, Chaabna K, Al-Kanaani Z, et al. (2017) Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions. *PLoS ONE* 12(10): e0187177. <https://doi.org/10.1371/journal.pone.0187177>

**Editor:** Ravi Jhaveri, University of North Carolina at Chapel Hill School of Medicine, UNITED STATES

**Received:** August 7, 2017

**Accepted:** October 13, 2017

**Published:** October 31, 2017

**Copyright:** © 2017 Harfouche et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This publication was made possible by NPRP grant number 9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The findings achieved herein are solely the responsibility of the authors. The authors are also grateful for infrastructure support provided by the Biostatistics, Epidemiology, and

Biomathematics Research Core at Weill Cornell Medicine-Qatar.

**Competing interests:** The authors have declared no competing interests exist.

HCV antibody prevalence in the background population, or sex. HCV viremic rate is a useful indicator to track the progress in (and coverage of) HCV treatment programs towards the set target of HCV elimination by 2030.

## Introduction

Viral hepatitis is ranked as the 7<sup>th</sup> leading cause of mortality worldwide [1], with nearly half of this mortality attributed to hepatitis C virus (HCV) [1]. Despite its global burden, the Middle East and North Africa (MENA) remains the most affected region [2, 3]. With the advent of direct-acting antivirals (DAAs) to treat and cure HCV infection [4], a global target was set to eliminate HCV infection by 2030 [5, 6].

A key feature of HCV natural history is that not all infected persons develop chronic infection [7–9]. While infected persons pass through a stage of acute infection for few months, and develop antibodies against HCV infection, a proportion of them spontaneously clear the infection and becomes HCV antibody (Ab) positive but HCV ribonucleic acid (RNA) negative [7–9]. The remainder of infected persons become chronic carriers of the infection and persist as HCV Ab positive and RNA positive [7–9]. For a given population, the proportion of chronically infected individuals (HCV Ab positive and RNA positive), out of all ever infected individuals (HCV Ab positive regardless of RNA status), defines the *HCV viremic rate* for this population [10].

Assessing and understanding the HCV viremic rate is critical for biological, epidemiological, and public health consequences. The HCV viremic rate provides a measure of HCV spontaneous clearance rate and its determinants, and how this rate may vary by population [11]. The HCV viremic rate furnishes also a direct measure of the likelihood that a member of a specific population is chronically infected, as well as an indirect measure of the risk of HCV reinfection in this population [11]. It is further essential for estimations of the number of HCV chronic carriers in different populations and countries, and consequences for resource allocation and development of screening and treatment programs. The HCV viremic rate will also play an increasingly important role in assessing and monitoring the progress in (and coverage of) HCV treatment programs in different populations, as we forge ahead towards HCV elimination by 2030.

The HCV viremic rate has been assessed through numerous studies in different populations globally, but its measures show extensive variability across studies [12–21]. The HCV clearance rate, which is strongly linked to HCV viremic rate [11], has been also assessed in multiple prospective cohort studies [7, 22–24], but its measures also show wide variation across studies [11]. To our knowledge, no study have yet been conducted to provide an overall pooled estimate and subgroup pooled estimates for the HCV viremic rate that factor the wide diversity of studies for this measure. No study has also investigated the sources of heterogeneity in available HCV viremic rate measures.

Against this background, we aimed in the present study to provide pooled estimates for the HCV viremic rate, overall and for different risk populations and different countries of the MENA region. We also aimed to investigate the sources of heterogeneity in available measures in MENA. These quantitative assessments were based on a comprehensive and standardized database of systematically gathered HCV viremic rate data.

This study was conducted as part of the MENA HCV Epidemiology Synthesis Project, an ongoing effort to characterize HCV epidemiology and inform public health research, resource allocation, policy, and programing priorities in MENA [11–21, 25, 26].

## Methodology

### Data sources

We retrieved studies reporting HCV RNA prevalence measures *strictly* among HCV Ab positive individuals from the MENA HCV Epidemiology Synthesis Project databases. These databases consist of 2,543 studies reporting HCV Ab prevalence among 52,598,736 participants, 47 studies reporting HCV Ab incidence among 29,600 participants, and 338 studies reporting HCV genotypes among 82,257 participants. The retrieved HCV RNA prevalence measures were nearly always extracted from studies whose main outcome measure was HCV Ab prevalence in some specific population. HCV RNA prevalence was a secondary outcome of these studies.

The HCV Synthesis Project databases were compiled through systematic reviews of the literature [12–17, 19–21] that were informed by the Cochrane Collaboration handbook [27], and reported as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [28]. The literature searches were conducted using broad search criteria with no language or year restrictions (S1 and S2 Boxes), and were based on international databases (PubMed and Embase), regional databases, national databases, and the MENA HIV/AIDS Epidemiology Synthesis Project database [29, 30]. Separate searches were also conducted for the non-indexed literature consisting of public health reports and routine data reporting. The flowcharts summarizing the searches can be found in the previous publications [12–17, 19–21]. The PRISMA checklist for the present study can be found in S1 Fig.

The definition of MENA for this project consisted of 24 countries including: Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, the United Arab Emirates (UAE), and Yemen.

### Study selection and classification

All studies reporting a measure of HCV viremic rate were included, provided the sample size was  $\geq 10$ . The HCV viremic rate was defined as the proportion of HCV Ab positive and RNA positive individuals out of all ever infected (i.e. HCV Ab positive) individuals in the sample. The overall sample size was replaced by stratified measures whenever this was possible while maintaining a subsample size  $\geq 10$ . The viremic rate measures were classified based on the perceived risk of HCV exposure, as informed by existing classifications [2, 12–17, 19–21], as follows:

1. General populations: populations at a low risk of being exposed to HCV infection such as blood donors, healthy adults, healthy children, and pregnant women, among others. Those referred to in included studies as “general populations” were labeled as *other general populations* to avoid confusion with the name of this category.
2. Populations at intermediate risk: populations at an intermediate risk of being exposed to HCV infection such as health care workers, diabetics, and prisoners, among others).
3. Populations at high risk of healthcare-related exposures: populations at a high risk of being exposed to HCV infection due to a medical condition that requires frequent injections or blood transfusions such as hemodialysis, thalassemia, and hemophilia patients, among others.

4. People who inject drugs (PWID) who are at a high risk of being exposed to HCV infection due to sharing of needles or syringes.
5. Populations with liver-related conditions: populations suffering from liver-related medical conditions that could be linked (or attributed) to HCV infection, such as viral hepatitis, hepatocellular carcinoma, and liver cirrhosis patients, among others.
6. Special clinical populations: populations with an undetermined risk of HCV exposure such as patients with malignancies, rheumatology disorders, and autoimmune diseases, among others.

## Quantitative analysis

**Meta-analyses.** We conducted meta-analyses to estimate the pooled mean HCV viremic rate for the different risk populations. The methods were adapted from earlier meta-analyses [12–21, 26]. We used DerSimonian-Laird random-effects models with inverse variance weighting whenever we had  $\geq 3$  measures to be pooled [31]. The Freeman-Tukey type arcsine square-root transformation was used to stabilize the variance of the proportion measures [32]. Heterogeneity in effect size between studies was assessed using the Cochran's Q test; a p-value  $< 0.1$  was considered significant [33, 34]. The  $I^2$  was used to assess the between-study variation associated with differences in effect size [33]. The prediction interval was calculated to identify the range where the true effect around the mean falls [33, 35].

Since we did not have sufficient number of studies to do a separate meta-analysis for each individual MENA country, we conducted meta-analyses by country or relevant subregional grouping (Afghanistan and Pakistan, Egypt, Fertile Crescent, Gulf, Iran, and Maghreb). The Fertile Crescent included Iraq, Jordan, Lebanon, Palestine, and Syria. The Gulf included Kuwait, Oman, and Saudi Arabia. The Maghreb included Algeria, Libya, Morocco, and Tunisia. This country/subregion classification included all MENA countries for which data on HCV viremic rate were available.

We further conducted meta-analyses for specific subpopulations among the general population (blood donors, children, pregnant women/antenatal care attendees, and other general populations), and specific subpopulations among the populations at high risk of healthcare-related exposures (hemophilia patients, hemodialysis patients, and thalassemia patients). We also conducted meta-analyses by sex (women only, men only, and mixed-sex), and by sampling method of the original study (convenience sampling, national population-based and probability-based sampling, and other probability-based sampling).

The meta-analyses were conducted using R studio version 3.3.2 [36] using the package meta [37].

**Meta-regressions and sources of heterogeneity.** We conducted univariable and multivariable random-effects meta-regressions to identify the predictors of higher HCV viremic rate and sources of between-study heterogeneity. The following independent variables were specified *a priori* because of epidemiological relevance: risk population, country or subregion, sex, age, HCV Ab prevalence of the sampled population, year of data collection, sample size, and sampling method. Variables with a p-value  $< 0.1$  in the univariable analyses were eligible for inclusion in the final multivariable model. Variables with a p-value  $< 0.05$  in the univariable models or the final multivariable model were considered statistically significant.

Risk population, country/subregion, and sex variables were categorized as described in the above sections. Age was categorized as children and adults. HCV Ab prevalence variable was coded as a categorical variable with four prevalence ranges: 1–10%, 10–30%, 30–50%, and  $> 50\%$ . The year of data collection variable was coded as a categorical variable with two date

ranges: before 2000 and 2000 and thereafter. The sample size variable was categorized as  $\geq 50$  and  $< 50$ . The sampling method variable was categorized as probability-based sampling and non-probability-based sampling.

For the year of data collection variable, we imputed the missing observations using the median of the results of the subtraction of the year of data collection from the year of publication. A sensitivity analysis using the imputed and the non-imputed observations revealed no impact on the statistical significance of the variable.

The meta-regressions were conducted using Stata/SE version 13 [38] using the package `metareg` [39].

## Results

### Scope of evidence

We identified 178 measures for HCV viremic rate among 19,593 HCV Ab positive individuals (Table 1). These measures included 81 in general populations, 20 in populations at intermediate risk, 51 in populations at high risk of healthcare-related exposures, five in PWID, eight in populations with liver-related conditions, and 12 in special clinical populations. One study was considered as “mixed” since the sample included a mix of general populations and an intermediate risk population [40].

There were data on HCV viremic rate in 16 out of the 24 MENA countries (Table 1). Egypt contributed the largest number of data points ( $n = 89$ ), and the majority of these were from studies in general populations.

### HCV viremic rate

HCV viremic rate varied across and within the risk populations with a broad range of 9–100% and a median of 68.8% (Table 2). The overall pooled mean HCV viremic rate (across all data points) was 67.6% (95% confidence interval (CI): 64.9–70.3%).

Across the risk populations (Table 2), the pooled mean HCV viremic rate was lowest at 57.4% (95% CI: 49.4–65.2%) in PWID, followed by 66.9% (95% CI: 62.6–71.1%) in the general populations, 67.1% (95% CI: 58.6–75.2%) in the populations at intermediate risk, 67.4% (95% CI: 56.7–77.3%) in the special clinical populations, 68.5% (95% CI: 63.5–73.3%) in the populations at high risk healthcare-related exposures, and 75.5% (95% CI: 61.0–87.6%) in populations with liver-related conditions.

Across countries or subregions (Table 3), the pooled mean HCV viremic rate was lowest at 62.1% (95% CI: 50.0–72.7%) in the Fertile Crescent, followed by 65.9% (95% CI: 55.3–75.9%) in the Gulf, 67.0% (95% CI: 63.1–70.8%) in Egypt, 68.6% (95% CI: 63.2–73.8%) in Iran, 70.4% (95% CI: 57.4–82.0%) in Afghanistan and Pakistan, and 70.4% (95% CI: 65.5–75.1%) in the Maghreb.

Among the general populations (Table 4), the pooled mean HCV viremic rate was lowest among children (54.0%, 95% CI: 37.6–70.0%), and highest among blood donors (76.3%, 95% CI: 68.6–84.0%). Among populations at high risk of healthcare-related exposures, the pooled mean HCV viremic rate was lowest among hemodialysis patients (66.5%, 95% CI: 59.9–73.2%), and highest among hemophilia patients (73.6%, 95% CI: 63.9–82.3%)

By sex (Table 4), the pooled mean HCV viremic rate was 65.4% (95% CI: 60.1–70.6%) among females, 67.4% (95% CI: 58.1–76.0%) among males, and 68.2% (95% CI: 64.9–71.3%) among the mixed-sex samples.

By sampling method (Table 4), the pooled mean HCV viremic rate was 58.7% (95% CI: 49.4–67.6%) for studies using probability-based sampling but not at the national level, 68.7%

**Table 1. Studies reporting hepatitis C virus (HCV) viremic rate stratified by risk population across countries of the Middle East and North Africa.**

Country	First author, year of publication	Years of data collection	Population description	Number of HCV Ab positive individuals tested for RNA	HCV viremic rate (%)
<b>General populations (n = 81)</b>					
Egypt	Abdel-Aziz, 2000 [46]	1997	Participants in a population-based survey	973	65.5
	AbdulQawi, 2011 [47]	2003–08	Pregnant women/ANC attendees	105	79.0
	Agha, 1998 [48]	1996–97	Pregnant women/ANC attendees	67	26.9
	Aguilar, 2008 [49]	-	General population	40	67.5
	Aguilar, 2008 [49]	-	General population	33	72.0
	Arafa, 2005 [50]	2002–03	Participants in a population-based survey	456	59.9
	Barakat, 2011 [51]	2005	Children	29	75.9
	Cowgill, 2004 [52]	1999–03	General population	80	65.0
	Darwish, 1995 [53]	-	Participants in a population-based survey	25	76.0
	Derbala, 2014 [54]	2008–10	General population	315	100
	El-Kamary, 2015 [55]	2012–13	Pregnant women/ANC attendees	52	58.0
	El-Karakasy, 2010 [56]	2006–07	Children	15	33.3
	El-Sadawy, 2004 [57]	-	Participants in a population-based survey	367	29.7
	El-Sherbini, 2003 [58]	1994	Children	17	41.0
	El-Zanaty, 2008 [41]	2008	15–19 years age group females in a national-based survey	178	67.8
	El-Zanaty, 2008 [41]	2008	20–24 years age group females in a national-based survey	153	66.9
	El-Zanaty, 2008 [41]	2008	25–29 years age group females in a national-based survey	94	62.9
	El-Zanaty, 2008 [41]	2008	30–34 years age group females in a national-based survey	134	70.2
	El-Zanaty, 2008 [41]	2008	35–39 years age group females in a national-based survey	129	69.3
	El-Zanaty, 2008 [41]	2008	40–44 years age group females in a national-based survey	122	65.2
	El-Zanaty, 2008 [41]	2008	45–49 years age group females in a national-based survey	109	60.0
	El-Zanaty, 2008 [41]	2008	50–54 years age group females in a national-based survey	85	70.4
	El-Zanaty, 2008 [41]	2008	55–59 years age group females in a national-based survey	107	68.8
	El-Zanaty, 2008 [41]	2008	10–14 years age group males in a national-based survey	68	76.7
	El-Zanaty, 2008 [41]	2008	20–24 years age group males in a national-based survey	65	62.6
	El-Zanaty, 2008 [41]	2008	25–29 years age group males in a national-based survey	62	73.8
	El-Zanaty, 2008 [41]	2008	30–34 years age group males in a national-based survey	59	53.6
	El-Zanaty, 2008 [41]	2008	35–39 years age group males in a national-based survey	54	66.2
	El-Zanaty, 2008 [41]	2008	40–44 years age group males in a national-based survey	50	61.1
	El-Zanaty, 2008 [41]	2008	45–49 years age group males in a national-based survey	42	65.0
	El-Zanaty, 2008 [41]	2008	50–54 years age group males in a national-based survey	32	74.6
	El-Zanaty, 2008 [41]	2008	55–59 years age group males in a national-based survey	28	71.1
	MoHP, 2015 [42]	2015	1–14 years age group females in a national-based survey	183	75.0
	MoHP, 2015 [42]	2015	15–19 years age group females in a national-based survey	164	66.5
	MoHP, 2015 [42]	2015	20–24 years age group females in a national-based survey	154	66.4
	MoHP, 2015 [42]	2015	25–29 years age group females in a national-based survey	61	81.1
	MoHP, 2015 [42]	2015	30–34 years age group females in a national-based survey	142	63.7
	MoHP, 2015 [42]	2015	35–39 years age group females in a national-based survey	106	69.5
	MoHP, 2015 [42]	2015	40–44 years age group females in a national-based survey	102	69.8
	MoHP, 2015 [42]	2015	45–49 years age group females in a national-based survey	85	75.1
	MoHP, 2015 [42]	2015	50–54 years age group females in a national-based survey	60	73.9
	MoHP, 2015 [42]	2015	55–59 years age group females in a national-based survey	69	73.4
	MoHP, 2015 [42]	2015	1–9 years age group males in a national-based survey	53	69.7
	MoHP, 2015 [42]	2015	10–14 years age group males in a national-based survey	57	57.5
	MoHP, 2015 [42]	2015	15–19 years age group males in a national-based survey	57	78.2
	MoHP, 2015 [42]	2015	20–24 years age group males in a national-based survey	35	68.4
	MoHP, 2015 [42]	2015	25–29 years age group males in a national-based survey	35	66.1
MoHP, 2015 [42]	2015	30–34 years age group males in a national-based survey	19	72.8	
MoHP, 2015 [42]	2015	35–39 years age group males in a national-based survey	17	42.6	
MoHP, 2015 [42]	2015	40–44 years age group males in a national-based survey	16	78.0	
MoHP, 2015 [42]	2015	45–49 years age group males in a national-based survey	14	70.6	
MoHP, 2015 [42]	2015	50–54 years age group males in a national-based survey	14	67.1	
MoHP, 2015 [42]	2015	55–59 years age group males in a national-based survey	12	27.5	
Jhaveri, 2015 [59]	2012–14	Pregnant women/ANC attendees	98	55.0	
Kalil, 2010 [60]	2004–05	Children	121	72.0	
Kassem, 2000 [61]	1996	Pregnant women/ANC attendees	19	73.7	
Khamis, 2014 [62]	-	Pregnant women/ANC attendees	20	45.0	
Kumar, 1997 [63]	1994–96	Pregnant women/ANC attendees	65	31.0	
Nafeh, 2000 [64]	-	Participants in a population-based survey	514	63.0	
Strickland, 2002 [65]	-	Healthy individuals	99	74.7	
Tanaka, 2004 [66]	1999	Blood donors	317	71.0	
Zuure, 2013 [67]	2009–10	General population	11	90.9	

(Continued)

Table 1. (Continued)

Country	First author, year of publication	Years of data collection	Population description	Number of HCV Ab positive individuals tested for RNA	HCV viremic rate (%)	
Iran	Doosti, 2009 [68]	2003–04	Blood donors	76	62.0	
	Farshadpour, 2010 [69]	2007–08	Blood donors	55	81.8	
Iraq	Obied, 2014 [70]	2012–13	Blood donors	20	65.0	
	Tawfeeq, 2013 [71]	2011–12	Blood donors	45	68.9	
Jordan	Rashdan, 2008 [72]	2004–06	Blood donors	29	89.6	
Morocco	Baha, 2013 [73]	2005–11	General population	195	70.9	
	Benouda, 2009 [74]	2005–07	General population	158	39.2	
Pakistan	Aziz, 2011 [75]	2005–09	Pregnant women/ANC attendees	640	79.7	
	Donchuk, 2016 [76]	2015–16	Outpatient hospital attendees	1,107	89.0	
	Idrees, 2008 [77]	1999–07	General population	857	49.2	
	Idrees, 2008 [77]	1999–07	General population	141	50.4	
	Karim, 2016 [78]	2015	Blood donors	60	93.0	
	Khokhar, 2004 [79]	2001–02	Pregnant women/ANC attendees	18	72.0	
	Rauf, 2011 [80]	2009	Refugees	18	44.4	
	Rauf, 2011 [80]	2009	Refugees	34	50.0	
	Palestine	Shemer-Avni, 1998 [81]	-	Blood donors	34	71.0
Shemer-Avni, 1998 [81]		-	Outpatient hospital attendees	11	64.0	
Tunisia	Mejri, 2005 [82]	1996	General population	72	82.0	
	Mejri, 2005 [82]	1996	General population	14	71.4	
<b>Populations at intermediate risk (n = 20)</b>						
Algeria	Mouffok, 2013 [83]	2003–12	HIV infected patients	22	54.5	
Egypt	Abdelwahab, 2012 [84]	2008–10	Diabetic patients	140	72.1	
	Chehadeh, 2011 [85]	-	Diabetic patients	20	80.0	
	Farghaly, 2014 [86]	-	Spouses of index patients	18	40.0	
	El-Karakasy, 2010 [56]	2006–07	Health care workers	25	66.7	
	Hassane, 1998 [87]	-	Household contacts of index patients	24	50.0	
	Hassane, 1998 [87]	-	Household contacts of index patients	21	59.1	
	Hassane, 1998 [87]	-	Household contacts of index patients	11	9.1	
	Madwar, 1999 [88]	-	Prisoners	28	100	
	Munier, 2013 [89]	2008–10	Diabetic patients	43	77.2	
	Mohamed, 2013 [90]	-	Health care workers	79	51.2	
	Shalaby, 2010 [91]	2007	Barbers and barbers' clients	77	73.0	
	Kuwait	Chehadeh, 2011 [85]	-	Diabetic patients (Kuwaitis)	11	72.7
		Chehadeh, 2011 [85]	-	Diabetic patients (Egyptians)	20	80.0
Lebanon	Mahfoud, 2010 [92]	2007–08	Prisoners	12	50.0	
Libya	Elzouki, 2014 [93]	2008–09	Health care workers	12	33.3	
Morocco	Cacoub, 2000 [94]	1995–96	Inpatients and outpatients	60	75.0	
	Rebbani, 2013 [95]	2006–10	HIV infected patients	27	77.8	
Pakistan	Qureshi, 2007 [96]	-	Health care workers	21	76.0	
	Zuberi, 2009 [97]	2004–08	Inpatients	10	90.0	
<b>Populations at high risk of healthcare-related exposures (n = 51)</b>						
Egypt	Abdelwahab, 2012 [98]	-	Hemophilia patients	40	47.5	
	Hussein, 2014 [99]	2007–08	Thalassemia patients	48	100	
	Omar, 2011 [100]	-	Thalassemia patients	75	74.3	
	Said, 2013 [101]	-	Thalassemia patients	47	100	
	Salama, 2015 [102]	-	Thalassemia patients	40	55.0	
Iran	Abdollahi, 2008 [103]	2003	Hemophilia patients	145	80.2	
	Alvai, 2005 [104]	2002	Thalassemia patients	13	84.6	
	Asguar, 2007 [105]	-	Hemophilia patients	21	80.9	
	Assarehzadegan, 2012 [106]	2008–09	Hemophilia patients	47	89.4	
	Azarkeivan, 2011 [107]	2008	Thalassemia patients	170	66.0	
	Broumand, 2002 [108]	-	Hemodialysis patients	105	48.6	
	Faranoush, 2006 [109]	-	Thalassemia patients	222	60.0	
	Ghane, 2012 [110]	2010	Thalassemia patients	36	77.8	
	Joukar, 2011 [111]	2009	Hemodialysis patients	61	50.8	
	Kalantari, 2011 [112]	2009	Thalassemia patients	50	62.0	
	Kalantari, 2011 [112]	2009	Hemophilia patients	495	70.1	
	Makhlough, 2008 [113]	2006	Hemodialysis patients	39	53.8	
	Mousavi, 2002 [114]	-	Thalassemia patients	22	77.3	
	Samimi-Rad, 2007 [115]	2004	Bleeding disorder patients	34	68.0	
	Samimi-Rad, 2008 [116]	2005	Hemodialysis patients	14	64.3	
	Ziaee, 2005 [117]	2000	Thalassemia patients	44	56.8	

(Continued)



Table 1. (Continued)

Country	First author, year of publication	Years of data collection	Population description	Number of HCV Ab positive individuals tested for RNA	HCV viremic rate (%)
Iraq	Al-Kubaisy, 2006 [118]	1998	Hemodialysis patients	50	76.0
	Al-Kubaisy, 2006 [118]	1998	Thalassemia patients	20	70.0
	Abdullah, 2012 [119]	2010	Hemophiliacs co-infected with HIV	92	26.1
	Khaled, 2014 [120]	2012	Thalassemia patients	50	88.0
	Shihab, 2014 [121]	2012–13	Hemodialysis patients	52	61.5
Jordan	Al-Sweedan, 2011 [122]	2008	Thalassemia patients	40	50.0
	Bdour, 2002 [123]	-	Hemodialysis patients	92	31.5
Lebanon	Abdelnour, 1997 [124]	-	Thalassemia patients	17	65.0
	Ramia, 2002 [125]	1999–00	Hemodialysis patients	55	34.5
Libya	Elzouki, 1995 [126]	-	Hemodialysis patients	32	72.0
Morocco	Benani, 1997 [127]	-	Hemodialysis patients	49	48.9
	Doblali, 2014 [128]	2010–12	Hemodialysis patients	26	65.4
	Foullous, 2015 [129]	-	Hemodialysis patients	194	54.1
	Lioussfi, 2014 [130]	2009	Hemodialysis patients	43	69.8
Oman	Al Naamani, 2015 [131]	1991–01	Thalassemia patients	65	51.0
Palestine	El-Ottol, 2010 [132]	2007	Hemodialysis patients	44	84.1
Saudi Arabia	Hussein, 1994 [133]	1993	Hemodialysis patients	27	70.4
Syria	Abdulkarim, 1998 [134]	-	Multi-transfused patients	56	87.5
	Yazaji, 2016 [135]	2012–13	Hemodialysis patients	18	22.2
Tunisia	Ayed, 2003 [136]	2001	Hemodialysis patients	310	75.5
	Ayed, 2003 [136]	2001	Hemodialysis patients	55	70.9
	Ayed, 2003 [136]	2001	Hemodialysis patients	44	90.9
	Ayed, 2003 [136]	2001	Hemodialysis patients	60	93.3
	Ayed, 2003 [136]	2001	Hemodialysis patients	243	60.5
	Ayed, 2003 [136]	2001	Hemodialysis patients	116	71.5
	Ben Othman, 2004 [137]	2000–02	Hemodialysis patients	42	76.2
	Ben Othman, 2004 [137]	2000–02	Hemodialysis patients	15	86.7
	Ben Othman, 2004 [137]	2000–02	Hemodialysis patients	33	78.8
	Hmaied, 2006 [138]	2001–03	Hemodialysis patients	79	73.0
	Sassi, 2000 [139]	-	Hemodialysis patients	27	51.8
<b>People who inject drugs (n = 5)</b>					
Afghanistan	Nasir, 2011 [140]	2006–08	People who inject drugs	165	58.2
	Nasir, 2011 [140]	2006–08	People who inject drugs	12	41.7
	Nasir, 2011 [140]	2006–08	People who inject drugs	44	59.1
Iran	Mansoori, 2003 [141]	1998–00	HIV patients with intravenous drug use as main mode of exposure	15	80.0
Lebanon	Mahfoud, 2010 [142]	2007–08	People who inject drugs	56	50.0
<b>Populations with liver-related conditions (n = 4)</b>					
Algeria	Bensalem, 2016 [143]	2012	Patients referred to a confirmatory laboratory test	3,204	66.2
Algeria, Morocco, Tunisia	Bahri, 2011 [144]	2002–05	Hepatocellular carcinoma patients	98	93.0
Egypt	Angelico, 1997 [145]	1993–95	Chronic liver disease patients	91	55.0
	Quinti, 1997 [146]	-	Acute viral hepatitis patients	23	87.0
	Strickland, 2002 [65]	-	Chronic liver disease patients	138	69.6
Iraq	Al-Kubaisy, 2014 [147]	2000–03	Hepatocellular carcinoma patients	17	70.8
Morocco	Tayeb, 2012 [148]	-	HCV Ab positive patients	46	43.5
Pakistan	Sundus, 2013 [149]	2009–10	Hepatitis patients	151	98.0
<b>Special clinical populations (n = 16)</b>					
Egypt	Cowgill, 2004 [52]	1999–03	Non-Hodgkin's lymphoma patients	106	89.0
	El Garf, 2012 [150]	2009	Rheumatoid arthritis patients	21	71.4
	Mahmoud, 2011 [151]	2009–10	Rheumatoid arthritis patients	22	63.6
	Mostafa, 2003 [152]	2000–01	Cancer patients on chemotherapy	13	38.5
	Mostafa, 2003 [152]	2000–01	Cancer patients on chemotherapy	44	47.7
	Sabry, 2005 [153]	-	Glomerulonephritis patients	90	55.6
	Sharaf-Eldeen, 2007 [154]	-	Lichen planus patients	43	76.8
	Youssef, 2009 [155]	-	Patients with liver complaints	156	57.7
Pakistan	Mahboob, 2003 [156]	1999–01	Lichen planus patients	16	62.5
Saudi Arabia	Halawani, 2012 [157]	2007–09	Urticarial patients	12	75.0
	Halawani, 2010 [158]	-	Lichen planus patients	24	62.5
Tunisia	Lakhoua Gorgi, 2010 [159]	1987–04	Renal transplant patients	24	91.7
<b>Mixed populations (n = 1)</b>					
Libya	Saleh, 1994 [40]	1992	Blood donors, health care workers, and outpatients	18	66.7

Abbreviations: Ab = Antibody, ANC = Antenatal care, HCV = Hepatitis C virus, MoHP = Ministry of Health and Population, RNA = Ribonucleic acid.

<https://doi.org/10.1371/journal.pone.0187177.t001>

**Table 2. Pooled mean estimate for hepatitis C virus (HCV) viremic rate by risk population in the Middle East and North Africa.**

Population at risk	Studies	HCV Ab prevalence <sup>a</sup>	HCV RNA positivity among HCV Ab positive individuals					
			Sample	Prevalence	Prevalence	Heterogeneity measures		
						Total N	Range (%)	Mean (95% CI)
General populations	81	10.4 (8.4–12.5)	10,448	26–100	66.9 (62.6–71.1)	1,510.9 (p < 0.0001)	94.7 (93.9–95.3)	29.1–95.3
Populations at intermediate risk	20	10.4 (6.8–14.6)	682	9–100	67.1 (58.6–75.2)	85.2 (p < 0.0001)	77.7 (66.0–85.4)	30.9–94.9
Populations at high risk healthcare-related exposures	51	31.3 (36.0–36.7)	3,814	22–100	68.5 (63.5–73.3)	478.0 (p < 0.0001)	89.5 (87.1–91.5)	33.7–94.8
People who inject drugs	5	42.2 (23.9–61.8)	292	50–80	57.4 (49.4–65.2)	5.6 (p = 0.23)	28.8 (0.0–72.3)	37.2–76.4
Populations with liver-related conditions	8	6.5 (43.8–83.0)	3,768	43–98	75.5 (61.0–87.6)	190.0 (p < 0.0001)	96.3 (94.5–97.5)	22.3–100
Special clinical populations	12	30.1 (19.6–41.8)	571	38–91	67.4 (56.7–77.3)	62.6 (p < 0.0001)	82.4 (70.6–89.5)	28.7–96.2
All studies <sup>e</sup>	<b>178</b>	<b>18.8 (16.7–21.1)</b>	<b>19,593</b>	<b>9–100</b>	<b>67.6 (64.9–70.3)</b>	<b>2,351.7 (p &lt; 0.0001)</b>	<b>92.5 (91.6–93.2)</b>	<b>33.7–93.8</b>

<sup>a</sup> This mean is the mean of HCV Ab prevalence in the study population from which the HCV viremic rate was extracted.

<sup>b</sup> Q: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size.

<sup>c</sup> I<sup>2</sup>: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.

<sup>d</sup> Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.

<sup>e</sup> A study including a mixed population group [40] was also considered in the meta-analysis.

Abbreviations: Ab = Antibody, CI = Confidence interval, HCV = Hepatitis C virus, RNA = Ribonucleic acid.

<https://doi.org/10.1371/journal.pone.0187177.t002>

(95% CI: 66.6–70.8%) for studies using probability-based sampling at the national level, and 68.2% (95% CI: 64.8–71.6%) in studies using convenience sampling.

There was (overall) evidence for strong heterogeneity in HCV viremic rate in all the different meta-analyses with generally a p-value < 0.0001 (Tables 2–4). The I<sup>2</sup> for the pooled estimates indicated that the vast majority of the variation was due to true variation in HCV viremic rate across studies rather than chance (generally I<sup>2</sup> >> 50%). The prediction intervals were generally very broad confirming substantial variation in measured HCV viremic rate across studies. Forest plots for the meta-analyses by risk population can be found in S2 Fig.

### Predictors of HCV viremic rate and sources of heterogeneity

Table 5 displays the results of the univariable meta-regressions to identify the predictors of HCV viremic rate and sources of between-study heterogeneity. None of the hypothesized predictors were statistically significant (p-value > 0.05), and none were eligible for inclusion in the final multivariable model (p-value > 0.1). Therefore, no multivariable meta-regression was conducted.

Though no variables were significantly predictive of HCV viremic rate, there were notably trends of lower viremic rate for females and children (Table 5), and trends of higher viremic rate for populations with liver-related conditions and for populations with high (> 50%) HCV Ab prevalence.

### Discussion

Through a comprehensive analysis of systematically extracted data, we investigated HCV viremic rate in the MENA region. We found that about two-thirds of HCV Ab positive individuals

**Table 3. Pooled mean estimate for hepatitis C virus (HCV) viremic rate by country or relevant subregion in the Middle East and North Africa.**

Country or relevant subregion	Studies	HCV Ab prevalence <sup>a</sup>	HCV RNA positivity among HCV Ab positive individuals					
			Sample			Prevalence		
			Total N	Mean (95% CI)	Total N	Range (%)	Mean (95% CI)	Heterogeneity measures
			Q <sup>b</sup> (p-value)	I <sup>2c</sup> (95% CI)	Prediction interval <sup>d</sup> (%)			
Afghanistan/Pakistan	15	20 (13.1–27.9)	3,294	41–98	70.4 (57.4–82.0)	628.9 (p < 0.0001)	97.8 (97.2–98.3)	17.1–100
Egypt	89	16.9 (14.2–19.9)	8,348	9–100	67.0 (63.1–70.8)	1,108.0 (p < 0.0001)	92.1 (90.8–93.1)	31.5–94.4
Fertile Crescent	20	18.4 (13.2–24.2)	810	22–89	62.1 (50.0–72.7)	182.9 (p < 0.0001)	89.6 (85.4–92.6)	14.2–98.6
Gulf	6	20.5 (7.9–36.9)	159	51–80	65.9 (55.3–75.9)	7.9 (p = 0.15)	37.2 (0.0–75.0)	38.9–88.7
Iran	19	28.6 (16.1–43.0)	1,664	48–89	68.6 (63.2–73.8)	74.3 (p < 0.0001)	75.8 (62.3–84.4)	46.8–86.9
Maghreb	29	18.2 (13.9–22.9)	5,318	33–93	70.4 (65.5–75.1)	222.7 (p < 0.0001)	87.4 (83.1–90.7)	45.0–90.7
All countries	<b>178</b>	<b>18.8 (16.7–21.1)</b>	<b>19,593</b>	<b>9–100</b>	<b>67.6 (64.9–70.3)</b>	<b>2,351.7 (p &lt; 0.0001)</b>	<b>92.5 (91.6–93.2)</b>	<b>33.7–93.8</b>

<sup>a</sup> This mean is the mean of HCV Ab prevalence in the study population from which the HCV viremic rate was extracted.

<sup>b</sup> Q: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size.

<sup>c</sup> I<sup>2</sup>: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.

<sup>d</sup> Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.

Abbreviations: Ab = Antibody, CI = Confidence interval, HCV = Hepatitis C virus, RNA = Ribonucleic acid.

<https://doi.org/10.1371/journal.pone.0187177.t003>

are chronically infected with HCV infection. Though the viremic rate varied widely across studies, the pooled mean HCV viremic rate was similar regardless of risk population or sub-population, country or subregion, HCV Ab prevalence, sex, or study sampling method. The overall pooled mean viremic rate of 67.6% (95% CI: 64.9–70.3%) was also similar to that found in large population-based and nationally-representative surveys such as those of the Demographic and Health Surveys in Egypt that reported a viremic rate of 66.6% (in 2008) [41] and 70.2% (in 2015) [42].

HCV viremic rate is defined as the proportion of *chronically infected* individuals (HCV Ab positive and RNA positive), out of all *ever infected* individuals (HCV Ab positive regardless of RNA status). Accordingly, it is closely linked to HCV clearance rate, defined as the proportion of people who spontaneously clear their infection—that is the proportion of people who clear their *acute infection* and do not become *chronically infected* [11]. Our results then imply that over 30% of infected individuals spontaneously clear their infection, a higher proportion than that estimated in prospective cohort studies of about 25% [7, 23]. While prospective studies provide a direct approach to estimating the clearance rate, there are known methodological limitations and potential biases that may lead to underestimation of clearance rate [7, 11, 22]. Our results, using an independent methodology from that of prospective studies, suggest that one-third of infected individuals spontaneously clear their infection.

In planning for this study, our implied hypothesis was that we will identify several predictors of higher HCV viremic rate. PWID and populations at high risk of healthcare-related exposures may have a weaker immune system and are at a higher risk of HCV reinfection, therefore should have a higher viremic rate. Female sex is associated with higher spontaneous clearance rate [7, 23, 43], and therefore we expected the viremic rate among men to be larger than that among women. We further expected a higher viremic rate in populations with higher

**Table 4. Pooled mean estimate for hepatitis C virus (HCV) viremic rate by risk subpopulation, sex, and sampling method in the Middle East and North Africa.**

Variables	Studies	HCV Ab prevalence <sup>a</sup>	HCV RNA positivity among HCV Ab positive individuals					
			Sample	Prevalence	Effect size	Heterogeneity measures		
	Total N	Mean (95% CI)	Total N	Range (%)	Mean (95% CI)	Q <sup>b</sup> (p-value)	I <sup>2c</sup> (95% CI)	Prediction interval <sup>d</sup> (%)
<b>Subpopulations among the general population</b>								
Blood donors	8	1.4 (0.5–2.7)	636	62–93	76.3 (68.6–84.0)	30.94 (p < 0.0001)	77.4 (55.2–88.6)	46.5–95.6
Children	7	3.7 (1.1–7.6)	225	27–75	54.0 (37.6–70.0)	26.1 (p < 0.0002)	77.0 (51.9–89.0)	7.6–96.4
Pregnant women/ANC attendees	9	7.7 (5.8–9.9)	1,084	26–79	58.1 (42.1–73.4)	149.3 (p < 0.0001)	94.6 (91.8–96.5)	7.4–99.2
Other general populations	57	13.9 (10.8–17.1)	8503	29–100	68.1 (62.9–73.1)	1,290.8 (p < 0.0001)	95.7 (94.9–96.3)	28.8–96.6
<b>Subpopulations among the populations at high risk healthcare-related exposures</b>								
Hemophilia patients	6	55.7 (35.6–74.9)	782	48–89	73.6 (63.9–82.3)	25.7 (p < 0.0001)	80.5 (58.0–91.0)	40.0–96.6
Hemodialysis patients	27	26.3 (22.0–30.1)	1,967	26–93	66.5 (59.5–73.2)	241.6 (p < 0.0001)	89.2 (85.6–92.0)	30.4–94.4
Thalassemia patients	16	29.6 (22.2–37.5)	1,027	34–100	72.1 (61.6–81.6)	177.5 (p < 0.0001)	91.5 (87.9–94.1)	26.3–99.9
<b>Sex</b>								
Females	33	11.0 (8.4–13.9)	2,712	26–100	65.4 (60.1–70.6)	225.5 (p < 0.0001)	85.8 (81.1–89.4)	36.3–89.6
Males	26	15.1 (10.4–20.5)	2,953	27–100	67.4 (58.1–76.0)	582.5 (p < 0.0001)	95.7 (94.6–96.6)	20.0–99.4
Mixed	119	22.5 (19.4–25.7)	13,928	9–100	68.2 (64.9–71.3)	1,542.1 (p < 0.0001)	92.3 (91.3–93.2)	34.9–93.9
<b>Sampling methods</b>								
Convenience sampling	126	22.4 (19.4–25.5)	13,713	9–100	68.2 (64.8–71.6)	1,843.8 (p < 0.0001)	93.2 (92.4–94.0)	31.5–95.6
National population-based and probability-based sampling	41	11.2 (7.9–14.9)	3,112	28–82	68.7 (66.6–70.8)	57.92 (p < 0.0003)	30.9 (0.0–53.1)	60.7–76.1
Other probability-based sampling	11	13.9 (5.9–24.5)	2,768	29–76	58.7 (49.4–67.6)	170.4 (p < 0.0001)	94.1 (91.3–96.0)	25.8–87.8

<sup>a</sup> This mean is the mean of HCV Ab prevalence in the study population from which the HCV viremic rate was extracted.

<sup>b</sup> Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in effect size.

<sup>c</sup> I<sup>2</sup>: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.

<sup>d</sup> Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.

Abbreviations: Ab = Antibody, ANC = Antenatal care, CI = Confidence interval, HCV = Hepatitis C virus, RNA = Ribonucleic acid.

<https://doi.org/10.1371/journal.pone.0187177.t004>

HCV Ab prevalence, as HCV Ab prevalence can be seen as a proxy for the risk of repeated HCV exposures. Lastly, we expected a higher viremic rate in populations with liver-related conditions, since the presence of these conditions could be indicative of chronic HCV infection.

Nevertheless, none of these hypothesized effects were identified as statistically significant in our meta-regression analyses. Though there was a trend of lower viremic rate in women-only studies, and trends of higher viremic rate in populations with liver-related conditions and populations with higher (>50%) HCV Ab prevalence, none of these trends reached statistical significance. These results suggest that either some of these effects may not be present as originally hypothesized, or that the effect size of these effects was not large enough to be

**Table 5. Univariable meta-regression models for hepatitis C virus (HCV) viremic rate in the Middle East and North Africa.**

		Number of studies	Univariable analysis	
			OR (95% CI)	p-value
<b>Risk population</b>	General populations	81	1	-
	Populations at intermediate risk	20	0.9 (0.6–1.6)	0.887
	Populations of high risk healthcare-related exposures	51	1.1 (0.8–1.5)	0.483
	PWID	5	0.6 (0.3–1.7)	0.375
	Populations with liver-related conditions	8	1.7 (0.8–3.6)	0.147
	Special clinical populations	12	1.0 (0.5–1.8)	0.97
<b>Region</b>	Egypt	89	1	-
	Afghanistan/Pakistan	15	1.2 (0.7–2.1)	0.541
	Fertile Crescent <sup>a</sup>	20	0.8 (0.5–1.3)	0.309
	Gulf <sup>b</sup>	6	1.0 (0.4–2.3)	0.971
	Iran	19	1.1 (0.6–1.8)	0.793
	Maghreb <sup>c</sup>	29	1.1 (0.7–1.7)	0.566
<b>Sex</b>	Females	33	1	-
	Males	26	1.1 (0.7–1.9)	0.66
	Mixed	119	1.1 (0.7–1.6)	0.559
<b>Age</b>	Children	14	1	-
	Adults	164	1.5 (0.9–2.6)	0.139
<b>Prevalence of HCV Ab positive</b>	1–10%	56	1	-
	10–30%	69	1.2 (0.8–1.7)	0.331
	30–50%	32	1.1 (0.7–1.8)	0.637
	>50%	16	1.6 (0.9–2.8)	0.113
<b>Year of data collection</b>	Before 2000	42	1	-
	2000 and thereafter	136	1.2 (0.9–1.7)	0.217
<b>Sample size</b>	<50	89	1	-
	≥50	89	1.0 (0.7–1.4)	0.75
<b>Sampling methods</b>	Non-probability based sampling	126	1	-
	Probability based sampling	50	0.8 (0.6–1.2)	0.272

<sup>a</sup> Fertile Crescent includes: Iraq, Jordan, Lebanon, Palestine, and Syria.

<sup>b</sup> Gulf includes: Kuwait, Oman, and Saudi Arabia.

<sup>c</sup> Maghreb includes: Algeria, Libya, Morocco, and Tunisia.

Abbreviations: Ab = Antibody, CI = Confidence interval, HCV = Hepatitis C virus, PWID = People who inject drugs, OR = Odds ratio.

<https://doi.org/10.1371/journal.pone.0187177.t005>

detected in our sample of 178 viremic rate measures, or that the heterogeneity in the effect size lowered the power of the analysis to detect these differences.

Though we could not identify any significant predictor of HCV viremic rate, the viremic rate varied widely across studies. This may suggest that much of this variation could be due to random effects, such as those related to the complex laboratory methods used in assessing the viremic rate. Assessment of HCV viremic rate requires a two-test algorithm, for HCV Ab and HCV RNA, and the diagnostic assays and protocols can vary from one study to another. Different assays, whether for HCV Ab or for HCV RNA, may also have different sensitivities and specificities, which can impact the estimated HCV viremic rate [44, 45]. Even small random errors in assessing the denominator (HCV Ab positive cases), or the numerator (HCV RNA positive cases), can lead to large variation in calculated viremic rate.

Another source of random errors in calculated HCV viremic rate could be sampling variation as the “effective” sample size in viremic rate studies (the number of HCV Ab positive

cases), tend to be small (Table 1). The number of HCV Ab positive cases is most often a *sub-sample* of the original study sample size—the original study sample size is the number of individuals recruited in the original study whose serostatus could be HCV Ab negative or HCV Ab positive. The median size of the (sub) sample of HCV Ab positive cases in included studies was only 50. With a viremic rate of 67.6% (as was the pooled estimate), this small median sample size leads to a wide confidence interval (95% CI: 53.3%-80.5%). This highlights how (sub) sample size could be a major cause of the observed variation.

The large variations in HCV viremic rate across studies (Table 1), but the small variations in the pooled mean HCV viremic rates (Tables 2–4), suggest caution against using the highly variable and possibly error-prone study-specific viremic rates in estimations of the number of HCV chronic carriers in different populations and countries, instead of the stable pooled means. We advocate here for the use of one standardized HCV viremic rate, say the overall pooled mean estimated in this study (Table 2), in ongoing chronic HCV infection estimations—such as the global estimations being conducted for the World Health Organization [3]. We further advocate for the use of pooled means, rather than study-specific estimates, for assessing and monitoring the progress in (and coverage of) HCV treatment programs, as we forge ahead towards HCV elimination by 2030. Of notice here that this progress monitoring will require repeated population-based measures of HCV antibody positivity and HCV RNA positivity in the same population, with sufficiently large sample sizes to assess statistically the trends in HCV viremic rate.

Our study has several limitations. The availability of data varied by risk population and country, and we did not identify any HCV viremic rate data for eight MENA countries. The number of studies was limited for some risk populations—only five studies were identified for PWID, and these were mostly conducted among PWID with access to prevention programs. Sample size varied across studies, and the sampled risk population may not have been representative of the wider risk population in the country. Despite these limitations, we identified a substantial volume of viremic rate data in MENA that facilitated the conduct of different types of analyses, thereby generating informative inferences.

## Conclusions

Two-thirds of HCV Ab positive individuals in MENA are chronically infected with HCV infection, implying that over 30% of infected individuals spontaneously clear their infection. Though there was extensive variation in the study-specific HCV viremic rates, the pooled mean viremic rates were similar regardless of risk population or subpopulation, country or subregion, HCV Ab prevalence in the background population, or sex. These findings argue for the use of one standardized HCV viremic rate, such as the overall pooled mean viremic rate provided in this study, in estimations of the number of HCV chronic carriers in different populations and countries. These findings also highlight the utility of using the pooled mean viremic rate as an indicator to track the progress in (and coverage of) HCV treatment programs in different risk populations and countries, as viral hepatitis treatment programs are established and/or expanded with the ultimate target of HCV elimination by 2030.

## Supporting information

**S1 Fig. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist.**  
(DOCX)

**S2 Fig. Forest plots presenting the outcomes for the pooled mean hepatitis C virus (HCV) viremic rate by risk population in the Middle East and North Africa.**

(DOCX)

**S1 Box. PubMed search strategies for systematically reviewing hepatitis C virus (HCV) in the Middle East and North Africa.**

(DOCX)

**S2 Box. Embase search strategies for systematically reviewing hepatitis C virus (HCV) in the Middle East and North Africa.**

(DOCX)

## Acknowledgments

This publication was made possible by NPRP grant number 9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The findings achieved herein are solely the responsibility of the authors. The authors are also grateful for infrastructure support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine-Qatar.

## Author Contributions

**Conceptualization:** Laith J. Abu-Raddad.

**Data curation:** Hiam Chemaitelly, Silva P. Kouyoumjian, Sarwat Mahmud, Karima Chaabna, Zaina Al-Kanaani.

**Formal analysis:** Manale Harfouche, Hiam Chemaitelly.

**Supervision:** Laith J. Abu-Raddad.

**Writing – original draft:** Manale Harfouche.

**Writing – review & editing:** Laith J. Abu-Raddad.

## References

1. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *The Lancet*. 2016; 388(10049):1081–8.
2. World Health Organization. The epidemiology of hepatitis C virus in the World Health Organization Eastern Mediterranean Region: Implications for strategic action. Eastern Mediterranean Hepatitis C Virus Epidemiology Synthesis Project. (in press). 2017.
3. World Health Organization. Global viral hepatitis report. Licence: CC BY-NC-SA 3.0 IGO. (<http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/>, accessed on May 2017). Geneva: World Health Organization.
4. Flamm SL. Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015. *Gastroenterology & Hepatology*. 2015; 11(6 Supplement 3):1–23.
5. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis World Health Organization (<http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/>, accessed on May 2017).
6. World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief World Health Organization (<http://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/>, accessed on May 2017).
7. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. *J Viral Hepat*. 2006; 13(1):34–41. <https://doi.org/10.1111/j.1365-2893.2005.00651.x> PMID: 16364080.

8. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. *Int J Med Sci.* 2006; 3(2):47–52. PMID: [16614742](https://pubmed.ncbi.nlm.nih.gov/16614742/)
9. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. *Nature Reviews Gastroenterology and Hepatology.* 2013; 10(9):553–62. <https://doi.org/10.1038/nrgastro.2013.107> PMID: [23817321](https://pubmed.ncbi.nlm.nih.gov/23817321/)
10. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10–12, 2002. *Hepatology.* 2002; 36(5B):s3–s20. <https://doi.org/10.1053/jhep.2002.37117> PMID: [12407572](https://pubmed.ncbi.nlm.nih.gov/12407572/)
11. Ayoub H, Chemaitelly H, Omori R, Abu Raddad LJ. Hepatitis C virus infection spontaneous clearance: are we underestimating it? (under preparation). 2017.
12. Al-Kanaani Z MS, Abu-Raddad L. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses (under preparation). 2017.
13. Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C virus epidemiology in Djibouti, Somalia, Sudan, and Yemen: systematic review and meta-analysis. *PloS one.* 2016; 11(2):e0149966. <https://doi.org/10.1371/journal.pone.0149966> PMID: [26900839](https://pubmed.ncbi.nlm.nih.gov/26900839/)
14. Chemaitelly H, Chaabna K, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Fertile Crescent: systematic review and meta-analysis. *PloS one.* 2015; 10(8):e0135281. <https://doi.org/10.1371/journal.pone.0135281> PMID: [26296200](https://pubmed.ncbi.nlm.nih.gov/26296200/)
15. Chemaitelly H, Mahmud S, Rahmani AM, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Afghanistan: Systematic review and meta-analysis. *International Journal of Infectious Diseases.* 2015; 40:54–63. <https://doi.org/10.1016/j.ijid.2015.09.011> PMID: [26417880](https://pubmed.ncbi.nlm.nih.gov/26417880/)
16. Fadlalla FA, Mohamoud YA, Mumtaz GR, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses. *PloS one.* 2015; 10(3):e0121873. <https://doi.org/10.1371/journal.pone.0121873> PMID: [25803848](https://pubmed.ncbi.nlm.nih.gov/25803848/)
17. Mahmud S, Akbarzadeh V, Abu-Raddad L. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses (under review). 2017.
18. Mahmud S, Al-Kanaani Z, Chaabna K, Chemaitelly H, Kouyoumjian SP, Abu Raddad LJ. Distribution, Diversity and Patterns of Hepatitis C Virus Genotypes in the Middle East and North Africa. *Journal of medical virology.* 2017.
19. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. *BMC infectious diseases.* 2013; 13(1):288.
20. Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. *International Journal of Infectious Diseases.* 2016; 46:116–25. <https://doi.org/10.1016/j.ijid.2016.03.012> PMID: [26996460](https://pubmed.ncbi.nlm.nih.gov/26996460/)
21. Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions (under review). 2017.
22. Amin J, Law M, Micallef J, Jauncey M, Van Beek I, Kaldor J, et al. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. *Epidemiology and infection.* 2007; 135(01):144–50.
23. Grebely J, Page K, Sacks-Davis R, Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. *Hepatology.* 2014; 59(1):109–20. <https://doi.org/10.1002/hep.26639> PMID: [23908124](https://pubmed.ncbi.nlm.nih.gov/23908124/)
24. Seeff LB. Natural history of chronic hepatitis C. *Hepatology.* 2002; 36(5B).
25. Chaabna K, Mohamoud YA, Chemaitelly H, Mumtaz GR, Abu-Raddad LJ. Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa. *Systematic reviews.* 2014; 3(1):146.
26. Harfouche M, Chemaitelly H, Mahmud S, Kouyoumjian S, Chaabna K, Al-Kanaani Z, et al. Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions (in press). 2017.
27. Van Tulder M, Furlan A, Bombardier C, Bouter L, Group EBotCCBR. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. *Spine.* 2003; 28(12):1290–9. <https://doi.org/10.1097/01.BRS.0000065484.95996.AF> PMID: [12811274](https://pubmed.ncbi.nlm.nih.gov/12811274/)
28. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS med.* 2009; 6(7):e1000097. <https://doi.org/10.1371/journal.pmed.1000097> PMID: [19621072](https://pubmed.ncbi.nlm.nih.gov/19621072/)
29. Akala FA, Semini I. Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: time for strategic action: World Bank Publications; 2010.



30. Abu-Raddad LJ, Hilmi N, Mumtaz G, Benkirane M, Akala FA, Riedner G, et al. Epidemiology of HIV infection in the Middle East and North Africa. *AidS*. 2010; 24:S5–S23.
31. Borenstein M, Hedges LV, Higgins J, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Research Synthesis Methods*. 2010; 1(2):97–111. <https://doi.org/10.1002/jrsm.12> PMID: 26061376
32. Freeman MF, Tukey JW. Transformations related to the angular and the square root. *The Annals of Mathematical Statistics*. 1950; 21(4):607–11.
33. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. *Front Matter*, in *Introduction to Meta-Analysis*. Chichester, UK: John Wiley & Sons, Ltd; 2009.
34. Higgin J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analysis. *British Medical Journal*. 2003; 327(7414):557–60. <https://doi.org/10.1136/bmj.327.7414.557> PMID: 12958120
35. Higgins J, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *Journal of the Royal Statistical Society: Series A (Statistics in Society)*. 2009; 172(1):137–59.
36. RStudio Team (2015). *RStudio: Integrated Development for R*. RStudio, Inc., Boston, MA URL <http://www.rstudio.com/>.
37. Schwarzer G. meta: An R package for meta-analysis. *R news*. 2007; 7(3):40–5.
38. StataCorp. 2015. *Stata Statistical Software: Release 14*. College Station, TX: StataCorp LP.
39. Harbord RM, Higgins JPT. Meta-regression in Stata. *Stata Journal*. 2008; 8(4):493–519.
40. Saleh MG, Pereira LM, Tibbs CJ, Ziu M, al-Fituri MO, Williams R, et al. High prevalence of hepatitis C virus in the normal Libyan population. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1994; 88(3):292–4. Epub 1994/05/01. PMID: 7974663.
41. El-Zanaty F, Way A. *Egypt Demographic and Health Survey 2008*. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International, 2009.
42. Ministry of Health and Population [Egypt], El-Zanaty and Associates [Egypt], and ICF International. *Egypt Health Issues Survey 2015*. Cairo, Egypt and Rockville, Maryland, USA: Ministry of Health and Population and ICF International: 2015.
43. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. *J Infect Dis*. 2009; 200(8):1216–26. <https://doi.org/10.1086/605947> PMID: 19764883
44. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. *Journal of viral hepatitis*. 2001; 8(2):87–95. PMID: 11264728
45. Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. *Asian journal of transfusion science*. 2014; 8(1):19. <https://doi.org/10.4103/0973-6247.126683> PMID: 24678168
46. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. *Hepatology*. 2000; 32(1):111–5. Epub 2000/06/28. <https://doi.org/10.1053/jhep.2000.8438> PMID: 10869297.
47. AbdulQawi K, Youssef A, Metwally MA, Ragih I, AbdulHamid M, Shaheen A. Prospective study of prevalence and risk factors for hepatitis C in pregnant Egyptian women and its transmission to their infants. *Croatian medical journal*. 2010; 51(3):219–28. Epub 2010/06/22. <https://doi.org/10.3325/cmj.2010.51.219> PMID: 20564765
48. Agha S, Sherif LS, Allam MA, Fawzy M. Transplacental transmission of hepatitis C virus in HIV-negative mothers. *Research in virology*. 1998; 149(4):229–34. Epub 1998/10/23. PMID: 9783338.
49. Aguilar CE, Soliman AS, McConnell DS, Zekri AR, Banerjee M, Omar A, et al. Androgen profiles among Egyptian adults considering liver status. *Journal of gastroenterology and hepatology*. 2008; 23(7 Pt 2):e137–45. Epub 2007/05/26. <https://doi.org/10.1111/j.1440-1746.2007.04949.x> PMID: 17524040
50. Arafa N, El-Hoseiny M, Rekecewicz C, Bakr I, El-Kafrawy S, El Daly M, et al. Changing pattern of hepatitis C virus spread in rural areas of Egypt. *Journal of hepatology*. 2005; 43(3):418–24. Epub 2005/07/16. <https://doi.org/10.1016/j.jhep.2005.03.021> PMID: 16019104.
51. Barakat S, Hafez S, Al-Bashir N. Hepatitis C virus infection in healthy Egyptian children: Prevalence and risk factors. *Journal of Pediatric Gastroenterology and Nutrition*. 2009; 48(11):E64–E5. <http://dx.doi.org/10.1097/MPG.0b013e3181aa06ea>.
52. Cowgill KD, Loffredo CA, Eissa SA-L, Mokhtar N, Abdel-Hamid M, Fahmy A, et al. Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. *International journal of epidemiology*. 2004; 33(5):1034–9. PMID: 15155696

53. Darwish NM, Abbas MO, Hady SI, Mohammed TA. Study of the high prevalence of HCV in Egypt. *The Journal of the Egyptian Public Health Association*. 1995; 70(3–4):397–414. Epub 1995/01/01. PMID: [17214166](https://pubmed.ncbi.nlm.nih.gov/17214166/).
54. Derbala M, Chandra P, Amer A JA, Sharma M, Amin A ea. Reexamination of the relationship between the prevalence of hepatitis C virus and parenteral antischistosomal therapy among Egyptians resident in Qatar. *Clin Exp Gastroenterol*. 2014; 7:427–33. <https://doi.org/10.2147/CEG.S65369> PMID: [25395869](https://pubmed.ncbi.nlm.nih.gov/25395869/)
55. El-Kamary SS, Hashem M, Saleh DA, Ehab M, Sharaf SA, El-Mougy F ea. Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. *J Infect* 2015; 70:512–9. <https://doi.org/10.1016/j.jinf.2015.01.009> PMID: [25623176](https://pubmed.ncbi.nlm.nih.gov/25623176/)
56. El-Karaksy H, Anwar GH, El-Raziky MS, El-Hawary M, Hashem M, El-Sayed R, et al. Anti-HCV prevalence among diabetic and non-diabetic Egyptian children. *Current diabetes reviews*. 2010; 6(6):388–92. Epub 2010/10/01. PMID: [20879976](https://pubmed.ncbi.nlm.nih.gov/20879976/).
57. El-Sadawy M, Ragab H, El-Toukhy H, el-Mor AL, Mangoud AM, Eissa MH, et al. Hepatitis C virus infection at Sharkia Governorate, Egypt: seroprevalence and associated risk factors. *J Egypt Soc Parasitol* 2004; 34(1 Suppl):367–84. PMID: [15124747](https://pubmed.ncbi.nlm.nih.gov/15124747/)
58. El-Sherbini A, Hassan W, Abdel-Hamid M, Naeim A. Natural history of hepatitis C virus among apparently normal schoolchildren: follow-up after 7 years. *Journal of tropical pediatrics*. 2003; 49(6):384–5. Epub 2004/01/17. PMID: [14725420](https://pubmed.ncbi.nlm.nih.gov/14725420/).
59. Jhaveri R, Hashem M, El-Kamary SS, Saleh DA, Sharaf SA, El-Mougy F ea. Hepatitis C Virus (HCV) Vertical Transmission in 12-Month-Old Infants Born to HCV-Infected Women and Assessment of Maternal Risk Factors. *Open Forum Infect Dis*. 2015; 2(2):ofv089. <https://doi.org/10.1093/ofid/ofv089> PMID: [26180831](https://pubmed.ncbi.nlm.nih.gov/26180831/)
60. Kalil KA, Farghally HS, Hassanein KM, Abd-Elsayed AA, Hassanein FE. Hepatitis C virus infection among paediatric patients attending University of Assiut Hospital, Egypt. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2010; 16(4):356–61. Epub 2010/08/28. PMID: [20795415](https://pubmed.ncbi.nlm.nih.gov/20795415/).
61. Kassem AS, el-Nawawy AA, Massoud MN, el-Nazar SY, Sobhi EM. Prevalence of hepatitis C virus (HCV) infection and its vertical transmission in Egyptian pregnant women and their newborns. *Journal of tropical pediatrics*. 2000; 46(4):231–3. Epub 2000/09/21. PMID: [10996985](https://pubmed.ncbi.nlm.nih.gov/10996985/).
62. Khamis HH, Farghaly AG, Shatat HZ, El-Ghitany EM. Prevalence of hepatitis C virus infection among pregnant women in a rural district in Egypt. *Tropical doctor*. 2014; 46(1):21–7. Epub 2014/12/18. <https://doi.org/10.1177/0049475514561330> PMID: [25515736](https://pubmed.ncbi.nlm.nih.gov/25515736/).
63. Kumar RM, Frossad PM, Hughes PF. Seroprevalence and mother-to-infant transmission of hepatitis C in asymptomatic Egyptian women. *European journal of obstetrics, gynecology, and reproductive biology*. 1997; 75(2):177–82. Epub 1998/02/03. PMID: [9447371](https://pubmed.ncbi.nlm.nih.gov/9447371/).
64. Nafeh MA, Medhat A, Shehata M, Mikhail NN, Swifee Y, Abdel-Hamid M, et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. *The American journal of tropical medicine and hygiene*. 2000; 63(5–6):236–41. Epub 2001/06/26. PMID: [11421370](https://pubmed.ncbi.nlm.nih.gov/11421370/).
65. Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, et al. Role of hepatitis C infection in chronic liver disease in Egypt. *The American journal of tropical medicine and hygiene*. 2002; 67(4):436–42. Epub 2002/11/28. PMID: [12452500](https://pubmed.ncbi.nlm.nih.gov/12452500/).
66. Tanaka Y, Agha S, Saady N, Kurbanov F, Orito E, Kato T, et al. Exponential spread of hepatitis C virus genotype 4a in Egypt. *Journal of molecular evolution*. 2004; 58(2):191–5. Epub 2004/03/26. <https://doi.org/10.1007/s00239-003-2541-3> PMID: [15042339](https://pubmed.ncbi.nlm.nih.gov/15042339/).
67. Zuure FR, Bouman J, Martens M, Vanhommerig JW, Urbanus AT, Davidovich U, et al. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. *Liver international: official journal of the International Association for the Study of the Liver*. 2013; 33(5):727–38. Epub 2013/03/02. <https://doi.org/10.1111/liv.12131> PMID: [23448397](https://pubmed.ncbi.nlm.nih.gov/23448397/).
68. Doosti A, Arnini-Bavil-Olyae S, Tajbakhsh E, Adeli A, Mahboudi F. Prevalence of viral hepatitis and molecular analysis of HBV among voluntary blood donors in west Iran. *New Microbiologica*. 2009; 32(2):193–8. PMID: [19579699](https://pubmed.ncbi.nlm.nih.gov/19579699/).
69. Farshadpour F, Makvandi M, Samarbafzadeh AR, Jalalifar MA. Determination of hepatitis C virus genotypes among blood donors in Ahvaz, Iran. *Indian Journal of Medical Microbiology*. 2010; 28(1):54–6. <https://doi.org/10.4103/0255-0857.58731> PMID: [20061766](https://pubmed.ncbi.nlm.nih.gov/20061766/).
70. Obied H, Alrodhan M, Mallah M. Molecular and immunological detection of hepatitis C virus infection among blood donors in Al-Muthanna province-Iraq. *International Journal of Advanced Research*. 2014; 2(6):295–315.

71. Tawfeeq W, Al-Aouadi R, Al-Yousif A. Detection of hepatitis C virus infection and genotypes among seropositive blood donors by polymerase chain reaction in babylon Governorate, Iraq. *Medical Journal of Babylon*. 2013; 10(1):25–37.
72. Rashdan A, Hijawi S, Jadallah K, Matalka I. Prevalence of hepatitis C virus antibodies among blood donors in Northern Jordan. *Jordan Medical Journal*. 2008; 42(3):179–83.
73. Baha W, Foulous A, Dersi N, They-they TP, El alaoui K, Nourichafi N, et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. *BMC public health*. 2013; 13(1):50. Epub 2013/01/22. <https://doi.org/10.1186/1471-2458-13-50> PMID: 23331910
74. Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M. Prevalence of hepatitis C virus infection in Morocco and serological tests assessment of detection for the viremia prediction. *Pathologie-biologie*. 2009; 57(5):368–72. Epub 2008/10/10. <https://doi.org/10.1016/j.patbio.2008.07.006> PMID: 18842351.
75. Aziz S, Hossain N, Karim SA, Rajper J, Soomro N, Noorulain W, et al. Vertical transmission of hepatitis C virus in low to middle socio-economic pregnant population of Karachi. *Hepato Int*. 2011; 5(2):677–80. <https://doi.org/10.1007/s12072-010-9229-8> PMID: 21484109
76. Donchuk D, Rossi G, Bjorklund Y, M. Zainal H, R. A, V. M. Hepatitis C treatment in a primary care clinic in the high HCV burden setting in Karachi, Pakistan. In: *Frontières MS*, editor. 2016.
77. Idrees M, Lal A, Naseem M, Khalid M. High prevalence of hepatitis C virus infection in the largest province of Pakistan. *Journal of digestive diseases*. 2008; 9(2):95–103. <https://doi.org/10.1111/j.1751-2980.2008.00329.x> PMID: 18419643
78. Karim F, Nasar A, Alam I, Alam I, Hassam S, Gul R. Incidence of active HCV infection amongst blood donors of Mardan District, Pakistan. *Asian Pac J Cancer Prev*. 2016; 17(1):235–8. PMID: 26838216
79. Khokhar N, Raja K, Javaid S. Seroprevalence of hepatitis C virus infection and its risk factors in pregnant women. *JPMA The Journal of the Pakistan Medical Association*. 2004; 54(3):135. PMID: 15129873
80. Rauf A, Nadeem MS, Ali A, Iqbal M, Mustafa M, Latif MM, et al. Prevalence of hepatitis B and C in internally displaced persons of war against terrorism in Swat, Pakistan. *The European Journal of Public Health*. 2011; 21(5):638–42. <https://doi.org/10.1093/eurpub/ckq084> PMID: 20601693
81. Shemer-Avni Y, el Astal Z, Kemper O, el Najjar KJ, Yaari A, Hanuka N, et al. Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. *Journal of medical virology*. 1998; 56(3):230–3. Epub 1998/10/23. PMID: 9783690.
82. Mejri S, Salah AB, Triki H, Alaya NB, Djebbi A, Dellagi K. Contrasting patterns of hepatitis C virus infection in two regions from Tunisia. *Journal of medical virology*. 2005; 76(2):185–93. Epub 2005/04/19. <https://doi.org/10.1002/jmv.20342> PMID: 15834884.
83. Mouffok NA, Bensadoun F, Belkadi AK. HCV infection in the hiv patient in oran Algeria. *Journal of Clinical and Experimental Hepatology*. 2013; 3(1):S38–S9.
84. Abdelwahab S, Rewisha E, Hashem M, Sobhy M, Galal I, Allam WR, et al. Risk factors for hepatitis C virus infection among Egyptian healthcare workers in a national liver diseases referral centre. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2012; 106(2):98–103. Epub 2011/12/27. <https://doi.org/10.1016/j.trstmh.2011.10.003> PMID: 22197011.
85. Chehadeh W, Kurien SS, Abdella N, Ben-Nakhi A, Al-Arouj M, Almuaili T, et al. Hepatitis C virus infection in a population with high incidence of type 2 diabetes: impact on diabetes complications. *Journal of infection and public health*. 2011; 4(4):200–6. Epub 2011/10/18. <https://doi.org/10.1016/j.jiph.2011.05.004> PMID: 22000848.
86. Farghaly HS, Metwalley KA, El-Hafeez HA. Hepatitis C virus infection in Egyptian children with type 1 diabetes mellitus: A single center study. *Indian journal of endocrinology and metabolism*. 2014; 18(2):197–201. Epub 2014/04/18. <https://doi.org/10.4103/2230-8210.129111> PMID: 24741516
87. Hassane FM, El-Shafie A, El-Ella SA, El-Gazzar F, Raof A, Adawy N. Horizontal Transmission of Hepatitis C Virus (HCV) in The Families of Children Positive For Hepatitis C. *Alexandria Journal of Pediatrics*. 1998; 12(1):209.
88. Madwar MA, El-Gindy I, Fahmy HM, Shoeb NM, Massoud BA. Hepatitis C virus transmission in family members of Egyptian patients with HCV related chronic liver disease. *The Journal of the Egyptian Public Health Association*. 1999; 74(3–4):313–32. Epub 2007/01/16. PMID: 17219873.
89. Munier A, Marzouk D, Abravanel F, El-Daly M, Taylor S, Mamdouh R, et al. Frequent transient hepatitis C viremia without seroconversion among healthcare workers in Cairo, Egypt. *PLoS One*. 2013; 8(2):e57835. Epub 2013/03/08. <https://doi.org/10.1371/journal.pone.0057835> PMID: 23469082
90. Mohamed HI, Saad ZM, Abd-Elreheem EM, Abd-ElGhany WM, Mohamed MS, Abd Elnaeem EA, et al. Hepatitis C, hepatitis B and HIV infection among Egyptian prisoners: seroprevalence, risk factors

- and related chronic liver diseases. *Journal of infection and public health*. 2013; 6(3):186–95. Epub 2013/05/15. <https://doi.org/10.1016/j.jiph.2012.12.003> PMID: 23668463.
91. Shalaby S, Kabbash I, El Saleet G, Mansour N, Omar A, El Nawawy A. Hepatitis B and C viral infection: prevalence, knowledge, attitude and practice among barbers and clients in Gharbia governorate, Egypt. *Eastern Mediterranean Health Journal*. 2010; 16(1):10–7. PMID: 20214151
  92. Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon. *Journal of infection in developing countries*. 2010; 4(3):144–9. Epub 2010/03/31. PMID: 20351454.
  93. Elzouki AN, Elgamay SM, Zorgani A, Elahmer O. Hepatitis B and C status among health care workers in the five main hospitals in eastern Libya. *Journal of infection and public health*. 2014; 7(6):534–41. Epub 2014/08/26. <https://doi.org/10.1016/j.jiph.2014.07.006> PMID: 25151657.
  94. Cacoub P, Ohayon V, Sekkat S, Dumont B, Sbai A, Lunel F, et al. Epidemiologic and virologic study of hepatitis C virus infections in Morocco. *Gastroenterologie clinique et biologique*. 2000; 24(2):169–73. Epub 2003/04/12. PMID: 12687957.
  95. Rebbani K, Ouladlarsen A, Bensghir A, Akil A, Lamdini H, Issouf H, et al. Co-infections with hepatitis B and C viruses in human immunodeficiency virus-infected patients in Morocco. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2013; 19(10):E454–7. Epub 2013/06/05. <https://doi.org/10.1111/1469-0691.12252> PMID: 23731409.
  96. Qureshi H, Arif A, Ahmed W, Alam SE. HCV exposure in spouses of the index cases. *JPMA The Journal of the Pakistan Medical Association*. 2007; 57(4):175. PMID: 17489523
  97. Zuberi BF, Zuberi FF, Hasan SR, Kumar R, Memon SA, Afsar S. Frequency of acute Hepatitis C after needle stick injury and its treatment outcome. *Pak J Med Sci*. 2009; 25(No.5):766–9.
  98. Abdelwahab MS, El-Raziky MS, Kaddah NA, Abou-Elew HH. Prevalence of hepatitis C virus infection and human immunodeficiency virus in a cohort of Egyptian hemophilic children. *Annals of Saudi medicine*. 2012; 32(2):200–2. Epub 2012/03/01. PMID: 22366833.
  99. Hussein E. Evaluation of infectious disease markers in multitransfused Egyptian children with thalassemia. *Ann Clin Lab Sci*. 2014; 44(1):62–6. PMID: 24695476
  100. Omar N, Salama K, Adolf S, El-Saeed GS, Abdel Ghaffar N, Ezzat N. Major risk of blood transfusion in hemolytic anemia patients. *Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis*. 2011; 22(4):280–4. Epub 2011/04/22. <https://doi.org/10.1097/MBC.0b013e3283451255> PMID: 21508832.
  101. Said F, El Beshlawy A, Hamdy M, El Raziky M, Sherif M, Ragab L. Intrafamilial transmission of hepatitis C infection in Egyptian multitransfused thalassemia patients. *Journal of tropical pediatrics*. 2013; 59(4):309–13. <https://doi.org/10.1093/tropej/fmt017> PMID: 23542535
  102. Salama KM, Ibrahim OM, Kaddah AM, Boseila S, Ismail LA, Abdel Hamid MM. Liver enzymes in children with beta-Thalassemia major: Correlation with iron overload and viral hepatitis. *Macedonian Journal of Medical Sciences*. 2015; 3(2):287–92. <http://dx.doi.org/10.3889/oamjms.2015.059>.
  103. Abdollahi A, Shahsiah R, Nassiri Toosi M, Lak M, Karimi K, Managhchi M, et al. Seroprevalence of Human Immunodeficiency Virus (HIV) and Hepatitis C Infection in Hemophilic Patients in Iran. *Iranian Journal of Pathology*. 2008; 3(3):119–24.
  104. Alvai S, Arzanian M, Hatami K, Shirani A. Frequency of hepatitis C in thalassemic patients and its association with liver enzyme, MOfid Hospital, Iran, 2002. *Pejouhesh*. 2005; 29(3):213–7.
  105. Asghar Z, Peyman M, Hadi A. Evaluation of HGV viremia prevalence and its co-infection with HBV, HCV, HIV and HTLV-1 in hemophilic patients of Southern Khorassan, Iran. *Hepatitis Monthly*. 2007; 2007(1):11–4.
  106. Assarehzadegan MA, Boroujerdnia MG, Zandian K. Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in Ahvaz, Southwest Iran. *Iranian Red Crescent Medical Journal*. 2012; 14(8):3.
  107. Azarkeivan A, Hajibeigy B, Afradi H, Eslami M, Ghazizadeh S, Shabeh Pour Z. Evaluation of clinical conditions of thalassemic patients having referred to Adult Thalassemia Center, Tehran. *Sci J Iran Blood Transfus Organ*. 2011; 8(1):32–41.
  108. Broumand B, Shamshirsaz AA, Kamgar M, Hashemi R, Aiazi F, Bekheirnia M, et al. Prevalence of hepatitis C infection and its risk factors in hemodialysis patients in tehran: preliminary report from "the effect of dialysis unit isolation on the incidence of hepatitis C in dialysis patients" project. *Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*. 2002; 13(4):467–72. Epub 2007/07/31. PMID: 17660669.

109. Faranoush M, Ghorbani R, Amin Bidokhti M, Yazdiha M, Malek M, Vosough P. Prevalence of Hepatitis C resulted from blood trasfusion in major thalassemia patients in Semnan, Damghab abd Garmsar (2002). *Medical Journal of Hormozgan University*. 2006; 10(1):77–82.
110. Ghane M, Eghbali M, Nejad HR, Saeb K, Farahani M. Distribution of hepatitis C virus genotypes amongst the beta-thalassemia patients in north of Iran. *Pakistan Journal of Biological Sciences*. 2012; 15(15):748–53. PMID: [24171261](#).
111. Joukar F, Besharati S, Mirpour H, Mansour-Ghanaei F. Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients. *Hepatitis monthly*. 2011; 11(3):178–81. Epub 2011/11/17. PMID: [22087139](#)
112. Kalantari H, Mirzabaghi A, Akbari M, Shahshahan Z. Prevalence of hepatitis C virus, hepatitis B virus, human immunodeficiency virus and related risk factors among hemophilia and thalassemia patients in Iran. *Iranian Journal of Clinical Infectious Diseases*. 2011; 6(2):82–4.
113. Makhloogh A, Jamshidi M, Mahdavi M. Hepatitis C prevalence studied by polymerase chain reaction and serological methods in haemodialysis patients in Mazandaran, Iran. *Singapore medical journal*. 2008; 49(11):921. PMID: [19037560](#)
114. Mousavi F, Ale Boyeh M. A-IFN treatment of hepatitis C in thalassemic patients Pejouhandeh. 2002; 7 (1 (27)):21–4.
115. Samimi Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. *Haemophilia*. 2007; 13(2):156–63. <https://doi.org/10.1111/j.1365-2516.2006.01415.x> PMID: [17286768](#)
116. Samimi-Rad K, Hosseini M. Hepatitis C virus infection and hcv genotypes of hemodialysis patients. *Iranian Journal of Public Health*. 2008; 37(3):146–52.
117. Ziaee M, Hassan F, Mohammad H, Chodsieh A. Evaluation of hepatitis C infection and its prevalence in hemophilic hemophilic patients in Khorasan [بررسی میزان ابتلا به هپاتیت C در بیماران هموفیل عضو کانوز هموفیلی C (خراسان)] (Persian). *Faq Knowledge*. 2005; 11(3):54–60.
118. Al-Kubaisy WA, Al-Naib KT, Habib MA. Prevalence of HCV/HIV co-infection among haemophilia patients in Baghdad. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2006; 12(3–4):264–9. Epub 2006/10/14. PMID: [17037693](#).
119. Abdullah AM, Hardan A, Latif II. Genotyping of hepatitis C virus isolates from Iraqi hemodialysis patients by reverse transcription-PCR and one step nested RT-PCR. *Diyala Journal of Medicine*. 2012; 3(1):9–18.
120. Khaled M. Prevalence of hepatitis B, hepatitis C and human immunodeficiency virus infection among Thalassemia patients in Ninavha Governorate/Iraq. *Journal of Biotechnology Research Center*. 2014; 8(2):11–3.
121. Shihab SS, Al-Hmudi HA, Al-Edani HS, Mahdi KH. Viral hepatitis infections in Basrah haemodialysis unit: serological diagnosis and viral loading. *European Journal of Experimental Biology*. 2014; 4 (2):106–12.
122. Al-Sweedan SA, Jaradat S, Amer K, Hayajneh W, Haddad H. Seroprevalence and genotyping of hepatitis C virus in multiple transfused Jordanian patients with beta-thalassemia major. [Turkish]. *Multipl transfuzyon uygulanan beta-talasemi majorlu urdunlu hastalarda hepatit c virusunun seroprevalansi {dotless} ve genotiplemesi*. *Turkish Journal of Hematology*. 2011; 28(1):47–51. <http://dx.doi.org/10.5152/tjh.2011.05>.
123. Bdour S. Hepatitis C virus infection in Jordanian haemodialysis units: serological diagnosis and genotyping. *Journal of medical microbiology*. 2002; 51(8):700–4. Epub 2002/08/13. <https://doi.org/10.1099/0022-1317-51-8-700> PMID: [12171303](#).
124. Abdelnour GE, Matar GM, Sharara HM, Abdelnour AM. Detection of anti-hepatitis C-virus antibodies and hepatitis C-virus RNA in Lebanese hemodialysis patients. *European journal of epidemiology*. 1997; 13(8):863–7. Epub 1998/02/26. PMID: [9476813](#).
125. Ramia S, Koussa S, Taher A, Haraki S, Klayme S, Sarkis D, et al. Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics. *Annals of tropical medicine and parasitology*. 2002; 96(2):197–202. Epub 2002/06/26. <https://doi.org/10.1179/000349802125000439> PMID: [12080981](#).
126. Elzouki AN, Bushala M, Tobji RS, Khfaifi M. Prevalence of anti-hepatitis C virus antibodies and hepatitis C virus viraemia in chronic haemodialysis patients in Libya. *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association*. 1995; 10(4):475–6. Epub 1995/01/01. PMID: [7542751](#).
127. Benani A, El-Turk J, Benjelloun S, Sekkat S, Nadifi S, Hda N, et al. HCV genotypes in Morocco. *Journal of medical virology*. 1997; 52(4):396–8. Epub 1997/08/01. PMID: [9260687](#).

128. Doblali T, Bahadi A, El Amrani M, Benyahia M. Prevalence and risk factors of hepatitis C virus infection in patients on hemodialysis: results of a Moroccan study. *Medecine et sante tropicales*. 2014; 24(4):375–8. Epub 2014/06/06. <https://doi.org/10.1684/mst.2014.0333> PMID: 24898543.
129. Foulous A, Mahmal S, Asdadi A, Mtioui N, Ouaddi F, siham Elkhyat S, et al. Epidemiological and virological study of hepatitis c virus infection in hemodialysis (case of six centers) in morocco. *J Biol Agric health*. 2015; 5(6):99–105.
130. Lioussfi Z, Errami Z, Radoui A, Rhou H, Ezzaitouni F, Ouzeddoun N, et al. Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. *Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*. 2014; 25(3):672–9. Epub 2014/05/14. PMID: 24821177.
131. Al-Naamani K, Al-Zakwani I, Al-Sinani S, Wasim F, Daar S. Prevalence of hepatitis C among multi-transfused thalassemia patients in the sultanate of Oman-single centre study. *Sultan Qaboos University Medical Journal*. 2015; 15(1):e46.
132. El-Ottol AE-kY, Elmanama AA, Ayesh BM. Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine. *Virology journal*. 2010; 7(1):210. Epub 2010/09/03. <https://doi.org/10.1186/1743-422x-7-210> PMID: 20809985
133. Hussein MM, Mooij JMV, Roujouleh H, El-Sayed H. Observations in a Saudi-Arabian dialysis population over a 13-year period. *Nephrology Dialysis Transplantation*. 1994; 9(8):1072–6.
134. Abdulkarim AS, Zein NN, Germer JJ, Kolbert CP, Kabbani L, Krajnik KL, et al. Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes. *The American journal of tropical medicine and hygiene*. 1998; 59(4):571–6. Epub 1998/10/28. PMID: 9790432.
135. Yazaji W, Habbal W, Monem F. Seropositivity of Hepatitis B and C among Syrian Multi-transfused Patients with Hemoglobinopathy. *Mediterranean journal of hematology and infectious diseases*. 2016; 8(1).
136. Ayed K, Gorgi Y, Ben Abdallah T, Aouadi H, Jendoubi-Ayed S, Sfar I, et al. Hepatitis C virus infection in hemodialysis patients from Tunisia: national survey by serologic and molecular methods. *Transplantation proceedings*. 2003; 35(7):2573–5. Epub 2003/11/13. PMID: 14612022.
137. Ben Othman S, Bouzgarrou N, Achour A, Bourlet T, Pozzetto B, Trabelsi A. High prevalence and incidence of hepatitis C virus infections among dialysis patients in the East-Centre of Tunisia. *Pathologie-biologie*. 2004; 52(6):323–7. Epub 2004/07/21. <https://doi.org/10.1016/j.patbio.2003.07.001> PMID: 15261374.
138. Hmaied F, Ben Mamou M, Saune-Sandres K, Rostaing L, Slim A, Arrouji Z, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. *Journal of medical virology*. 2006; 78(2):185–91. Epub 2005/12/24. <https://doi.org/10.1002/jmv.20526> PMID: 16372289.
139. Sassi F, Gorgi Y, Ayed K, Abdallah TB, Lamouchi A, Maiz HB. Hepatitis C virus antibodies in dialysis patients in Tunisia: a single center study. *Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*. 2000; 11(2):218–22. Epub 2008/01/23. PMID: 18209319.
140. Nasir A, Todd CS, Stanekzai MR, Bautista CT, Botros BA, Scott PT, et al. Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities. *The International journal on drug policy*. 2011; 22(2):145–52. Epub 2010/12/15. <https://doi.org/10.1016/j.drugpo.2010.10.006> PMID: 21146392.
141. Mansoori SD, Zadsar M, Arami S, Adimi P, Alaei K, Velayati AA. Immunological and clinical features of HIV in a group of hospitalized Iranian patients. *Archives of Iranian Medicine*. 2003; 6(1):5–8.
142. Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. *Virology journal*. 2010; 7(1):96. Epub 2010/05/15. <https://doi.org/10.1186/1743-422x-7-96> PMID: 20465784
143. Bensalem A, Selmani K, Narjes H, Bencherifa N, Mostefaoui F, Keriou C, et al. Eastern region represents a worrying cluster of active hepatitis C in Algeria in 2012. *Journal of medical virology*. 2016; 88(8):1394–403. Epub 2016/02/10. <https://doi.org/10.1002/jmv.24491> PMID: 26856380.
144. Bahri O, Ezzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AE, Mestiri H, et al. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. *World journal of hepatology*. 2011; 3(1):24–30. Epub 2011/02/11. <https://doi.org/10.4254/wjh.v3.i1.24> PMID: 21307984
145. Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, et al. Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. *Journal of hepatology*. 1997; 26(2):236–43. Epub 1997/02/01. PMID: 9059941.

146. Quinti I, el-Salman D, Monier MK, Hackbart BG, Darwish MS, el-Zamiaty D, et al. HCV infection in Egyptian patients with acute hepatitis. *Digestive diseases and sciences*. 1997; 42(10):2017–23. Epub 1997/11/19. PMID: [9365128](#).
147. Al-Kubaisy W. A., Obaid K. J., Noor N. M., Ibrahim N. S., Al-Azawi A. A. Hepatitis C virus prevalence and genotyping among hepatocellular carcinoma patients in Baghdad. *Asian pacific Journal of Cancer Prevention*. 2014; 15(18):7725–30. PMID: [25292053](#)
148. Tayeb Z, El Bakkouri J, Fellah H. Correlation between viral load and the degree of liver fibrosis in patients suffering from viral hepatitis C. *Clinical Chemistry and Laboratory Medicine*. 2012; 50(4): A131.
149. Sundus A, Siddique O, Ibrahim MF, Abbasi Z, Aziz S. Hepatitis patients lost to follow-up at a liver centre in a tertiary care hospital of Karachi, Pakistan—a cross-sectional descriptive study. *JPMA The Journal of the Pakistan Medical Association*. 2013; 63(12):1566–70. PMID: [24397113](#)
150. El Garf A, El Zorkany B, Gheith R, Sheba H, Abdel Moneim G, El Garf K. Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward. *Rheumatology international*. 2012; 32(9):2691–5. Epub 2011/07/28. <https://doi.org/10.1007/s00296-011-2014-8> PMID: [21792648](#).
151. Mahmoud GA, Zayed HS, Sherif MM, Mostafa MM. Characteristics of rheumatoid arthritis patients with concomitant hepatitis C virus infection. *Egyptian Rheumatologist*. 2011; 33(3):139–45. <http://dx.doi.org/10.1016/j.ejr.2011.05.003>.
152. Mostafa A, Ebeid E, Mansour T, Amin M, Sidhom I, Khaeiry A, et al. Seroprevalence of hepatitis B and C in pediatric malignancies. *Journal of the Egyptian National Cancer Institute*. 2003; 15:33–42.
153. Sabry A, A EA, Sheashaa H, El-Husseini A, Mohamed Taha N, Elbaz M, et al. HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis. *Virology*. 2005; 334(1):10–6. Epub 2005/03/08. <https://doi.org/10.1016/j.virol.2005.01.013> PMID: [15749118](#).
154. Sharaf-Eldeen S, Salama K, Eldemerdash S, Hassan HMS, Semesem M. Hepatitis B and C Viruses in Egyptian children with malignancy. *Journal of Medical Sciences*. 2007; 7(6):1003–8.
155. Youssef A, Yano Y, Utsumi T, abd El-alah EM, abd El-Hameed Ael E, Serwah Ael H, et al. Molecular epidemiological study of hepatitis viruses in Ismailia, Egypt. *Intervirology*. 2009; 52(3):123–31. Epub 2009/05/27. <https://doi.org/10.1159/000219385> PMID: [19468235](#).
156. Mahboob A, Haroon T, Iqbal Z, Iqbal F, Butt A. Frequency of anti-HCV antibodies in patients with lichen planus. *Journal of the College of Physicians and Surgeons—Pakistan: JCPSP*. 2003; 13(5):248–51. <https://doi.org/05.2003/JCPSP.248251> PMID: [12757670](#)
157. Halawani M, Bakir TM. Determination of hepatitis C virus genotypes in pruritus patients in Saudi Arabia. *Genetic Testing and Molecular Biomarkers*. 2012; 16(1):46–9. <http://dx.doi.org/10.1089/gtmb.2011.0064>. PMID: [21967468](#).
158. Halawani M, Balbisi A, Alotaibi H, Alsaif F, Bakir TM. The prevalence of HCV antibodies in skin disease patients in Saudi Arabia. *Saudi Pharmaceutical Journal*. 2010; 18(1):35–9. <http://dx.doi.org/10.1016/j.jsps.2009.12.003>. PMID: [23960718](#).
159. Lakhoua Gorgi Y, Gorgi F, Madkouri G, Abderrahim E, Sfar I, Ramadani B, et al. Hepatitis C in kidney transplantation: comparative study between two Maghreb centers: Casablanca and Tunis. *La Tunisie medicale*. 2010; 88(12):902–9. Epub 2010/12/08. PMID: [21136358](#).